Short answer
Stryker Corporation (SYK) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 11 to 12 directors, increasing governance capacity and adding an independent healthcare executive.
Stryker Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 11 to 12 directors, increasing governance capacity and adding an independent healthcare executive
- James E. Davis joins effective January 1, 2027, bringing CEO experience at Quest Diagnostics and prior medical-device leadership
- No Board committee assignment initially, limiting immediate influence over audit, compensation or governance functions
- Compensation aligned with Stryker’s other nonemployee directors, with standard director indemnification protections
Item 7.01 · Regulation FD Disclosure
- Stryker elected Mr. Davis to its board, expanding or changing board oversight
- Exhibit 99.1 contains the company’s announcement and related director details
Item EX-99.1 · Exhibit EX-99.1
- Board nomination of Jim Davis effective January 1, 2027, pending election
- Davis brings CEO experience at Quest Diagnostics and prior leadership of GE’s MRI business
- Medical technology and global healthcare expertise strengthens board oversight of Stryker’s strategy
- Leadership addition relevant to investors, but no immediate financial impact or compensation terms disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stryker Corporation 8-K filings
Get the next SYK 8-K as it lands
Follow SYK for push alerts, or ask the research agent what this filing means.